Increased Expressions of Programmed Death Ligand 1 and Galectin 9 in Transplant Recipients Who Achieved Tolerance After Immunosuppression Withdrawal
Copyright © 2021 American Association for the Study of Liver Diseases..
Programmed death 1 (PD1)/its ligand PD-L1 concomitant with T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)/its ligand galectin 9 (Gal-9) and the forkhead box P3 (FOXP3) might be involved in tolerance after liver transplantation (LT). Liver biopsies from 38 tolerant, 19 nontolerant (including 16 samples that triggered reintroduction of immunosuppression [IS] and 19 samples after IS reintroduction), and 38 control LT patients were studied. The expressions of PD1, PD-L1, Gal-9, and FOXP3 were determined by immunohistochemical and immunofluorescence (IF) staining. The success period of IS withdrawal was calculated using Kaplan-Meier curve analysis. Tolerant and control patients exhibited higher PD-L1, Gal-9, and FOXP3 levels than nontolerant patients at the moment of triggering IS reintroduction. High expressions of PD-L1 and Gal-9 were associated with prolonged success of tolerance (83.3% versus 36.7% [P < 0.01] and 73.1% versus 42.9% [P = 0.03]). A strong correlation between PD-L1 and Gal-9 expression levels was detected (Spearman r = 0.73; P ≤ 0.001), and IF demonstrated colocalization of PD-L1 and Gal-9 in the cytoplasm of hepatocytes. In conclusion, the present study demonstrated that increased expressions of PD-L1 and Gal-9 were associated with sustained tolerance after IS withdrawal in pediatric liver transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society - 28(2022), 4 vom: 01. Apr., Seite 647-658 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hai Nam, Nguyen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B7-H1 Antigen |
|---|
| Anmerkungen: |
Date Completed 25.04.2022 Date Revised 09.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/lt.26336 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331959593 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331959593 | ||
| 003 | DE-627 | ||
| 005 | 20231225214624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/lt.26336 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331959593 | ||
| 035 | |a (NLM)34655506 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hai Nam, Nguyen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased Expressions of Programmed Death Ligand 1 and Galectin 9 in Transplant Recipients Who Achieved Tolerance After Immunosuppression Withdrawal |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2022 | ||
| 500 | |a Date Revised 09.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 American Association for the Study of Liver Diseases. | ||
| 520 | |a Programmed death 1 (PD1)/its ligand PD-L1 concomitant with T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)/its ligand galectin 9 (Gal-9) and the forkhead box P3 (FOXP3) might be involved in tolerance after liver transplantation (LT). Liver biopsies from 38 tolerant, 19 nontolerant (including 16 samples that triggered reintroduction of immunosuppression [IS] and 19 samples after IS reintroduction), and 38 control LT patients were studied. The expressions of PD1, PD-L1, Gal-9, and FOXP3 were determined by immunohistochemical and immunofluorescence (IF) staining. The success period of IS withdrawal was calculated using Kaplan-Meier curve analysis. Tolerant and control patients exhibited higher PD-L1, Gal-9, and FOXP3 levels than nontolerant patients at the moment of triggering IS reintroduction. High expressions of PD-L1 and Gal-9 were associated with prolonged success of tolerance (83.3% versus 36.7% [P < 0.01] and 73.1% versus 42.9% [P = 0.03]). A strong correlation between PD-L1 and Gal-9 expression levels was detected (Spearman r = 0.73; P ≤ 0.001), and IF demonstrated colocalization of PD-L1 and Gal-9 in the cytoplasm of hepatocytes. In conclusion, the present study demonstrated that increased expressions of PD-L1 and Gal-9 were associated with sustained tolerance after IS withdrawal in pediatric liver transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Forkhead Transcription Factors |2 NLM | |
| 650 | 7 | |a Galectins |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 700 | 1 | |a Taura, Kojiro |e verfasserin |4 aut | |
| 700 | 1 | |a Koyama, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Nishio, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Gen |e verfasserin |4 aut | |
| 700 | 1 | |a Uemoto, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Xuefeng, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Daichi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Eri |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshizawa, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Iwaisako, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yoh, Tomoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hata, Koichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Masui, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Okajima, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Haga, Hironori |e verfasserin |4 aut | |
| 700 | 1 | |a Uemoto, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Hatano, Etsuro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society |d 2000 |g 28(2022), 4 vom: 01. Apr., Seite 647-658 |w (DE-627)NLM105775185 |x 1527-6473 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:647-658 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/lt.26336 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 4 |b 01 |c 04 |h 647-658 | ||